Key Points
- Director Robert Malenka sold 11,264 shares at an average price of $18.42 for a total of $207,482.88, trimming his stake by 3.34% to 325,795 shares (about $6.0M post-sale).
- Maplight reported a steep quarterly loss of ($37.18) EPS, missing expectations by $35.32; the stock trades near $18 with a 52‑week range of $12.24–$21.55 and a market cap of roughly $818M.
- Wall Street coverage is mostly positive — multiple firms initiated Buy/Outperform ratings and the consensus price target is about $31 (MarketBeat: "Moderate Buy").
Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) Director Robert Malenka sold 736 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $18.15, for a total transaction of $13,358.40. Following the transaction, the director directly owned 325,059 shares in the company, valued at approximately $5,899,820.85. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.
Maplight Therapeutics Price Performance
Shares of MPLT opened at $18.02 on Wednesday. Maplight Therapeutics, Inc. has a 1-year low of $12.24 and a 1-year high of $21.55. The company has a market cap of $817.57 million and a price-to-earnings ratio of -0.48. The company's 50-day moving average is $17.83.
Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last posted its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).
Hedge Funds Weigh In On Maplight Therapeutics
A number of hedge funds have recently added to or reduced their stakes in MPLT. Fcpm Iii Services B.V. bought a new position in Maplight Therapeutics in the 4th quarter valued at approximately $56,672,000. T. Rowe Price Investment Management Inc. bought a new stake in Maplight Therapeutics in the 4th quarter worth about $49,154,000. Goldman Sachs Group Inc. bought a new position in Maplight Therapeutics during the 4th quarter valued at about $34,026,000. Nan Fung Group Holdings Ltd purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at about $17,060,000. Finally, 5AM Venture Management LLC bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth approximately $16,687,000.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on the company. Morgan Stanley assumed coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set an "overweight" rating and a $34.00 price objective for the company. Zacks Research raised shares of Maplight Therapeutics to a "hold" rating in a research report on Monday, November 24th. Stifel Nicolaus began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a "buy" rating and a $28.00 price objective on the stock. Jefferies Financial Group began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set a "buy" rating and a $32.00 target price for the company. Finally, Wall Street Zen upgraded Maplight Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, December 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Maplight Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $31.00.
View Our Latest Report on MPLT
About Maplight Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
